Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis

Schizophrenia Research

Volumn 140, Issue 1-3, 2012, Pages 214-220

  Yilmaz, Zeynep ^a,c   Zai, Clement C ^b,c   Hwang, Rudi ^a,c   Mann, Steve ^c   Arenovich, Tamara ^c   Remington, Gary ^a,b,c   Daskalakis, Zafiris J ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotic medication response; Clinical improvement; Dopamine D2 receptor occupancy; Meta analysis; Neuroimaging; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RACLOPRIDE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84865338145     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.06.027     Document Type: Article

References (44)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(14):8104-8109.
2. Agid O., Mamo D., Ginovart N., Vitcu I., Wilson A.A., Zipursky R.B., Kapur S. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007, 32(6):1209-1215.
3. Agid O., Kapur S., Remington G. Emerging drugs for schizophrenia. Expert Opin. Emerg. Drugs 2008, 13(3):479-495.
4. Barnas C., Quiner S., Tauscher J., Hilger E., Willeit M., Kufferle B., Asenbaum S., Brucke T., Rao M.L., Kasper S. In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacology (Berl) 2001, 157(3):236-242.
5. Barnes T.R., Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 2011, 25(5):383-399.
6. Bernardo M., Parellada E., Lomena F., Catafau A.M., Font M., Gomez J.C., Lopez-Carrero C., Gutierrez F., Pavia J., Salamero M. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Psychiatry Res. 2001, 107(2):87-97.
7. Bressan R.A., Erlandsson K., Jones H.M., Mulligan R.S., Ell P.J., Pilowsky L.S. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J. Clin. Psychopharmacol. 2003, 23(1):5-14.
8. Bullich S., Cot A., Gallego J., Gunn R.N., Suárez M., Pavía J., Ros D., Laruelle M., Catafau A.M. Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: comparison to 11C-Raclopride PET. Neuroimage 2010, 50(4):1511-1518.
9. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh) 1963, 20:140-144.
10. Catafau A.M., Suarez M., Bullich S., Llop J., Nucci G., Gunn R.N., Brittain C., Laruelle M. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage 2009, 46(2):447-458. Barcelona Clinical Imaging in Psychiatry Group.
11. Corripio I., Catafau A.M., Perez V., Puigdemont D., Mena E., Aguilar Y., Carrio I., Alvarez E. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29(1):91-96.
12. Emsley R. Drugs in development for the treatment of schizophrenia. Expert Opin. Investig. Drugs 2009, 18(8):1103-1118.
13. Farde L., Wiesel F.A., Jansson P., Uppfeldt G., Wahlen A., Sedvall G. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl) 1988, 94(1):1-7.
14. Gefvert O., Lundberg T., Wieselgren I.M., Bergstrom M., Langstrom B., Wiesel F., Lindstrom L. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol. 2001, 11(2):105-110.
15. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch. Gen. Psychiatry 2012, (Apr 2. (Epub ahead of print)).
16. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63(10):1079-1087.
17. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097. EUFEST study group.
18. Kane J.M. Treatment-resistant schizophrenic patients. J. Clin. Psychiatry 1996, 57(Suppl. 9):35-40.
19. Kapur S., Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 2001, 50(11):873-883.
20. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry 2001, 158(3):360-369.
21. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry 1998, 155(7):921-928.
22. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157(4):514-520.
23. Kapur S., Zipursky R., Jones C., Shammi C.S., Remington G., Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry 2000, 57(6):553-559.
24. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
25. Mamo D., Graff A., Mizrahi R., Shammi C.M., Romeyer F., Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry 2007, 164(9):1411-1417.
26. Mamo D., Kapur S., Keshavan M., Laruelle M., Taylor C.C., Kothare P.A., Barsoum P., McDonnell D. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008, 33(2):298-304.
27. Marder S.R., Roth B., Sullivan P.F., Scolnick E.M., Nestler E.J., Geyer M.A., Welnberger D.R., Karayiorgou M., Guidotti A., Gingrich J., Akbarian S., Buchanan R.W., Lieberman J.A., Conn P.J., Haggarty S.J., Law A.J., Campbell B., Krystal J.H., Moghaddam B., Saw A., Caron M.G., George S.R., Allen J.A., Solis M. Advancing drug discovery for schizophrenia. Ann. N. Y. Acad. Sci. 2011, 1236:30-43.
28. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?. Fed. Proc. 1973, 32(2):200-205.
29. Meisenzahl E.M., Schmitt G., Grunder G., Dresel S., Frodl T., la Fougere C., Scheuerecker J., Schwarz M., Boerner R., Stauss J., Hahn K., Moller H.J. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 2008, 41(5):169-175.
30. Mezler M., Geneste H., Gault L., Marek G.J. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr. Opin. Investig. Drugs 2010, 11(7):833-845.
31. Moresco R.M., Cavallaro R., Messa C., Bravi D., Gobbo C., Galli L., Lucignani G., Colombo C., Rizzo G., Velona I., Smeraldi E., Fazio F. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J. Psychopharmacol. 2004, 18(3):355-365.
32. Nordstrom A.L., Nyberg S., Olsson H., Farde L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch. Gen. Psychiatry 1998, 55(3):283-284.
33. Nyberg S., Eriksson B., Oxenstierna G., Halldin C., Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am. J. Psychiatry 1999, 156(6):869-875.
34. Perala J., Suvisaari J., Saarni S.I., Kuoppasalmi K., Isometsa E., Pirkola S., Partonen T., Tuulio-Henriksson A., Hintikka J., Kieseppa T., Harkanen T., Koskinen S., Lonnqvist J. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 2007, 64(1):19-28.
35. Scatton B., Claustre Y., Cudennec A., Oblin A., Perrault G., Sanger D.J., Schoemaker H. Amisulpride: from animal pharmacology to therapeutic action. Int. Clin. Psychopharmacol. 1997, 12(Suppl. 2):S29-S36.
36. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry 1998, 3(2):123-134.
37. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261(5562):717-719.
38. Tauscher-Wisniewski S., Kapur S., Tauscher J., Jones C., Daskalakis Z.J., Papatheodorou G., Epstein I., Christensen B.K., Zipursky R.B. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J. Clin. Psychiatry 2002, 63(11):992-997.
39. Tort A.B., Souza D.O., Lara D.R. Theoretical insights into the mechanism of action of atypical antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30(4):541-548.
40. Uchida H., Mamo D.C., Kapur S., Labelle A., Shammi C., Mannaert E.J., Mann S.W., Remington G. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J. Clin. Psychiatry 2008, 69(8):1281-1286.
41. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011, 31(4):497-502.
42. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374(9690):635-645.
43. van Rossum J.M. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther. 1966, 160(2):492-494.
44. Zink M., Englisch S., Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry 2010, 23(2):103-111.